Xeris Expects to Exceed Full-Year 2024 Financial Guidance
Portfolio Pulse from
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announced it expects to exceed its full-year 2024 financial guidance, projecting total revenue of $203 million, surpassing the previous guidance of $198 million to $202 million. The company also anticipates ending 2024 with over $71 million in cash and generating positive cash flow in the fourth quarter.
January 10, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xeris Biopharma Holdings, Inc. expects to exceed its 2024 revenue guidance, projecting $203 million, surpassing the previous range of $198 million to $202 million. The company also anticipates positive cash flow in Q4 and ending 2024 with over $71 million in cash.
Xeris Biopharma's announcement of exceeding its revenue guidance and expecting positive cash flow in Q4 is a positive indicator for investors. The projected revenue of $203 million surpasses the previous guidance, suggesting strong business performance. This news is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100